P. Angus, R. Vaughan, S. Xiong, H. Yang, W. Delaney et al., Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase, Gastroenterology, vol.125, issue.2, pp.292-299, 2003.
DOI : 10.1016/S0016-5085(03)00939-9

F. Bani-sadr, P. Palmer, C. Scieux, and J. M. Molina, Ninety???Six???Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV???1 and Wild???Type Hepatitis B Virus, Clinical Infectious Diseases, vol.39, issue.7, pp.1062-1066, 2004.
DOI : 10.1086/424012

Y. Benhamou, R. Tubiana, and V. Thibault, Tenofovir Disoproxil Fumarate in Patients with HIV and Lamivudine-Resistant Hepatitis B Virus, New England Journal of Medicine, vol.348, issue.2, pp.177-185, 2003.
DOI : 10.1056/NEJM200301093480218

M. N. Brunelle, A. C. Jacquard, C. Pichoud, D. Durantel, S. Carrouee-durantel et al., Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir, Hepatology, vol.64, issue.6, pp.1391-1398, 2005.
DOI : 10.1002/hep.20723
URL : https://hal.archives-ouvertes.fr/inserm-00133179

M. Buti, M. Cotrina, R. Jardi, E. C. De-castro, F. Rodriguez-frias et al., Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B, Journal of Viral Hepatitis, vol.22, issue.4, pp.270-275, 2001.
DOI : 10.1053/jhep.2000.19622

T. T. Chang, R. G. Gish, R. De-man, A. Gadano, J. Sollano et al., A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1001-1011, 2006.
DOI : 10.1056/NEJMoa051285

T. T. Chang, R. G. Gish, S. J. Hadziyannis, J. Cianciara, M. Rizzetto et al., A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients, Gastroenterology, vol.129, issue.4, pp.1198-209, 2005.
DOI : 10.1053/j.gastro.2005.06.055

R. N. Chien, Y. F. Liaw, and M. Atkins, Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B, Hepatology, vol.114, issue.3, pp.770-774, 1999.
DOI : 10.1002/hep.510300313

R. J. Colonno, R. Rose, S. Levine, J. Baldick, K. Pokornowski et al., Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients, Hepatology, vol.42, issue.suppl1, pp.962-573, 2005.

R. De-franchis, A. Hadengue, G. Lau, D. Lavanchy, A. Lok et al., Consensus statement (long version), International Consensus Conference on Hepatitis B. 13, pp.3-25, 2002.

W. E. Delaney, R. Edwards, D. Colledge, T. Shaw, J. Torresi et al., Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus, Antimicrobial Agents and Chemotherapy, vol.45, issue.6, pp.1705-1718, 2001.
DOI : 10.1128/AAC.45.6.1705-1713.2001

D. Marco, V. Marzano, A. Lampertico, P. Andreone, P. Santantonio et al., Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine, Hepatology, vol.348, issue.4, pp.883-91, 2004.
DOI : 10.1002/hep.20381

J. L. Dienstag, R. D. Goldin, E. J. Heathcote, H. W. Hann, M. Woessner et al., Histological outcome during long-term lamivudine therapy, Gastroenterology, vol.124, issue.1, pp.105-122, 2003.
DOI : 10.1053/gast.2003.50013

J. L. Dienstag, E. R. Schiff, T. L. Wright, R. P. Perrillo, H. W. Hann et al., Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States, New England Journal of Medicine, vol.341, issue.17, pp.1256-1263, 1999.
DOI : 10.1056/NEJM199910213411702

G. J. Dore, D. A. Cooper, A. L. Pozniak, E. Dejesus, L. Zhong et al., Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy???Naive and ???Experienced Patients Coinfected with HIV???1 and Hepatitis B Virus, The Journal of Infectious Diseases, vol.189, issue.7, pp.1185-92, 2004.
DOI : 10.1086/380398

D. Durantel, S. Carrouee-durantel, B. Werle-lapostolle, M. N. Brunelle, C. Pichoud et al., A new strategy for studyingin vitro the drug susceptibility of clinical isolates of human hepatitis B virus, Hepatology, vol.281, issue.4, pp.855-64, 2004.
DOI : 10.1002/hep.20388

L. Fu and Y. C. Cheng, Characterization of Novel Human Hepatoma Cell Lines with Stable Hepatitis B Virus Secretion for Evaluating New Compounds against Lamivudine- and Penciclovir-Resistant Virus, Process Citation], pp.3402-3409, 2000.
DOI : 10.1128/AAC.44.12.3402-3407.2000

S. K. Fung, P. Andreone, S. H. Han, R. Reddy, K. Regev et al., Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation, Journal of Hepatology, vol.43, issue.6, pp.937-980, 2005.
DOI : 10.1016/j.jhep.2005.05.037

R. Gish, T. T. Chang, and R. A. De-man, Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients, Hepatology, vol.42, issue.suppl1, pp.181-267, 2005.

R. G. Gish, H. Trinh, N. Leung, F. K. Chan, M. W. Fried et al., Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study, Journal of Hepatology, vol.43, issue.1, pp.60-66, 2005.
DOI : 10.1016/j.jhep.2005.02.017

S. Hadziyannis, N. Tassopoulos, and T. Chang, P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy, Journal of Clinical Virology, vol.36, issue.1, pp.14-745, 2005.
DOI : 10.1016/S1386-6532(06)80284-2

S. J. Hadziyannis, G. V. Papatheodoridis, E. Dimou, A. Laras, and C. Papaioannou, Efficacy of longterm lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B, Hepatology, vol.324, issue.1, pp.847-51, 2000.

S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis et al., Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.352, issue.26, pp.2673-81, 2005.
DOI : 10.1056/NEJMoa042957

S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis et al., Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen???Negative Chronic Hepatitis B, New England Journal of Medicine, vol.348, issue.9, pp.800-807, 2003.
DOI : 10.1056/NEJMoa021812

H. L. Janssen, M. Van-zonneveld, H. Senturk, S. Zeuzem, U. S. Akarca et al., Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, The Lancet, vol.365, issue.9454, pp.123-132, 2005.
DOI : 10.1016/S0140-6736(05)17701-0

J. Korenman, B. Baker, J. Waggoner, J. E. Everhart, D. Bisceglie et al., Long-Term Remission of Chronic Hepatitis B after Alpha-Interferon Therapy, Annals of Internal Medicine, vol.114, issue.8, pp.629-663, 1991.
DOI : 10.7326/0003-4819-114-8-629

K. Lacombe, J. Gozlan, P. Y. Boelle, L. Serfaty, F. Zoulim et al., Long-term hepatitis B virus dynamics in HIV???hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate, AIDS, vol.19, issue.9, pp.907-915, 2005.
DOI : 10.1097/01.aids.0000171404.07995.5c

C. Lai, E. Gane, and Y. Liaw, Telbivudine versus lamivudine for chronic hepatitis B: first year results from the interantional phase III globe trial, Hepatology, vol.42, p.748, 2005.

C. L. Lai, R. W. Chine, N. W. Leung, T. T. Chang, R. Guan et al., A One-Year Trial of Lamivudine for Chronic Hepatitis B, New England Journal of Medicine, vol.339, issue.2, pp.61-68, 1998.
DOI : 10.1056/NEJM199807093390201

C. L. Lai, J. Dienstag, E. Schiff, N. W. Leung, M. Atkins et al., Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B, Clinical Infectious Diseases, vol.36, issue.6, pp.687-96, 2003.
DOI : 10.1086/368083

C. L. Lai, N. Leung, E. K. Teo, M. Tong, F. Wong et al., A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen???Positive Chronic Hepatitis B, Gastroenterology, vol.129, issue.2, pp.528-564, 2005.
DOI : 10.1016/j.gastro.2005.05.053

C. L. Lai, S. G. Lim, N. A. Brown, X. J. Zhou, D. M. Lloyd et al., A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection, Hepatology, vol.5, issue.3, pp.719-745, 2004.
DOI : 10.1002/hep.20374

C. L. Lai, M. Rosmawati, J. Lao, H. Van-vlierberghe, F. H. Anderson et al., Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection, Gastroenterology, vol.123, issue.6, pp.1831-1839, 2002.
DOI : 10.1053/gast.2002.37058

C. L. Lai, D. Shouval, A. S. Lok, T. T. Chang, H. Cheinquer et al., Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1011-1031, 2006.
DOI : 10.1056/NEJMoa051287

P. Lampertico, D. Ninno, E. Manzin, A. Donato, M. F. Rumi et al., A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum, Hepatology, vol.26, issue.6, pp.1621-1626, 1997.
DOI : 10.1002/hep.510260634

P. Lampertico, M. Vigano, E. Manenti, M. Iavarone, G. Lunghi et al., Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine, Hepatology, vol.126, issue.6, pp.1414-1419, 2005.
DOI : 10.1002/hep.20939

G. K. Lau, T. Piratvisuth, K. X. Luo, P. Marcellin, S. Thongsawat et al., Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B, New England Journal of Medicine, vol.352, issue.26, pp.2682-95, 2005.
DOI : 10.1056/NEJMoa043470

N. W. Leung, C. L. Lai, T. T. Chang, R. Guan, C. M. Lee et al., Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy, Hepatology, vol.33, issue.6, pp.1527-1559, 2001.
DOI : 10.1053/jhep.2001.25084

S. Levine, D. Hernandez, G. Yamanaka, S. Zhang, R. Rose et al., Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro, Antimicrobial Agents and Chemotherapy, vol.46, issue.8, pp.2525-2557, 2002.
DOI : 10.1128/AAC.46.8.2525-2532.2002

Y. F. Liaw, J. J. Sung, W. C. Chow, G. Farrell, C. Z. Lee et al., Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease, New England Journal of Medicine, vol.351, issue.15, pp.1521-1552, 2004.
DOI : 10.1056/NEJMoa033364

A. S. Lok, H. T. Chung, V. W. Liu, and O. C. Ma, Long-term follow-up of chronic hepatitis B patients treated with interferon alfa, Gastroenterology, vol.105, issue.6, pp.1833-1841, 1993.
DOI : 10.1016/0016-5085(93)91082-S

A. S. Lok, C. L. Lai, N. Leung, G. B. Yao, Z. Y. Cui et al., Long-term safety of lamivudine treatment in patients with chronic hepatitis B, Gastroenterology, vol.125, issue.6, pp.1714-1736, 2003.
DOI : 10.1053/j.gastro.2003.09.033

A. S. Lok and B. J. Mcmahon, Chronic hepatitis B, Hepatology, vol.34, issue.6, pp.1225-1266, 2001.
DOI : 10.1053/jhep.2001.29401

A. S. Lok and B. J. Mcmahon, Chronic hepatitis B: Update of recommendations, Hepatology, vol.36, issue.3, pp.857-61, 2004.
DOI : 10.1002/hep.20110

A. S. Lok, F. Zoulim, S. Locarnini, A. Mangia, G. Niro et al., Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay, Journal of Clinical Microbiology, vol.40, issue.10, pp.3729-3763, 2002.
DOI : 10.1128/JCM.40.10.3729-3734.2002

E. K. Manesis and S. J. Hadziyannis, Interferon ?? Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B, Gastroenterology, vol.121, issue.1, pp.101-110, 2001.
DOI : 10.1053/gast.2001.25524

P. Marcellin, T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert et al., Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen???Positive Chronic Hepatitis B, New England Journal of Medicine, vol.348, issue.9, pp.808-824, 2003.
DOI : 10.1056/NEJMoa020681

P. Marcellin, G. K. Lau, F. Bonino, P. Farci, S. Hadziyannis et al., Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.351, issue.12, pp.1206-1223, 2004.
DOI : 10.1056/NEJMoa040431

S. Menne, C. A. Roneker, B. E. Korba, J. L. Gerin, B. C. Tennant et al., Immunization with Surface Antigen Vaccine Alone and after Treatment with 1-(2-Fluoro-5-Methyl-??-L-Arabinofuranosyl)-Uracil (L-FMAU) Breaks Humoral and Cell-Mediated Immune Tolerance in Chronic Woodchuck Hepatitis Virus Infection, Journal of Virology, vol.76, issue.11, pp.5305-5319, 2002.
DOI : 10.1128/JVI.76.11.5305-5314.2002

S. Nafa, S. Ahmed, D. Tavan, C. Pichoud, F. Berby et al., Early Detection of Viral Resistance by Determination of Hepatitis B Virus Polymerase Mutations in Patients Treated by Lamivudine for Chronic Hepatitis B, Hepatology, vol.28, issue.5, pp.1078-1088, 2000.
DOI : 10.1053/jhep.2000.19619

G. V. Papatheodoridis, E. Dimou, A. Laras, V. Papadimitropoulos, and S. J. Hadziyannis, Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease, Hepatology, vol.32, issue.1, pp.219-245, 2002.
DOI : 10.1053/jhep.2002.33894

R. Perillo, E. Schiff, G. Davis, H. C. Bodenheimer, K. Lindsay et al., A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B, New England Journal of Medicine, vol.323, issue.5, pp.295-301, 1990.
DOI : 10.1056/NEJM199008023230503

R. Perrillo, H. W. Hann, D. Mutimer, B. Willems, N. Leung et al., Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus, Gastroenterology, vol.126, issue.1, pp.81-90, 2004.
DOI : 10.1053/j.gastro.2003.10.050

M. G. Peters, H. Hann-hw, P. Martin, E. J. Heathcote, P. Buggisch et al., Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary???s Hospital, London, England); C. Trepo (Hopital H??tel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ)., Gastroenterology, vol.126, issue.1, pp.91-101, 2004.
DOI : 10.1053/j.gastro.2003.10.051

G. Realdi, G. Fattovich, S. Hadzyiannis, S. Schalm, P. Almasio et al., Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study, Journal of Hepatology, vol.21, issue.4, pp.656-666, 1994.
DOI : 10.1016/S0168-8278(94)80115-0

M. Rizzetto, Efficacy of lamivudine in HBeAg-negative chronic hepatitis B, Journal of Medical Virology, vol.48, issue.4, pp.435-51, 2002.
DOI : 10.1002/jmv.2164

M. Rizzetto, N. C. Tassopoulos, R. D. Goldin, R. Esteban, T. Santantonio et al., Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B, Journal of Hepatology, vol.42, issue.2, pp.173-182, 2005.
DOI : 10.1016/j.jhep.2004.10.006

B. Seigneres, C. Pichoud, P. Martin, P. Furman, C. Trepo et al., Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses, Hepatology, vol.46, issue.3, pp.710-732, 2002.
DOI : 10.1053/jhep.2002.35070

J. J. Sung, M. L. Wong, S. Bowden, C. T. Liew, A. Y. Hui et al., Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy, Gastroenterology, vol.128, issue.7, pp.1890-1897, 2005.
DOI : 10.1053/j.gastro.2005.03.009

N. C. Tassopoulos, R. Volpes, G. Pastore, J. Heathcote, M. Buti et al., Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B, Process Citation], pp.889-96, 1999.
DOI : 10.1097/00042737-199904000-00026

D. J. Tenney, S. M. Levine, R. E. Rose, A. W. Walsh, S. P. Weinheimer et al., Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine, Antimicrobial Agents and Chemotherapy, vol.48, issue.9, pp.3498-507, 2004.
DOI : 10.1128/AAC.48.9.3498-3507.2004

F. Van-bommel, T. Wunsche, S. Mauss, P. Reinke, A. Bergk et al., Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection, Hepatology, vol.125, issue.6, pp.1421-1426, 2004.
DOI : 10.1002/hep.20464

J. P. Villeneuve, D. Durantel, S. Durantel, C. Westland, S. Xiong et al., Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient, Journal of Hepatology, vol.39, issue.6, pp.1085-1094, 2003.
DOI : 10.1016/j.jhep.2003.09.022

S. Villet, C. Pichoud, A. Ollivet, J. P. Villeneuve, C. Trepo et al., Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus, Hepatology, vol.42, issue.1, pp.981-581, 2005.

B. Werle, K. Cinquin, P. Marcellin, S. Pol, M. Maynard et al., Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy, Journal of Viral Hepatitis, vol.40, issue.1, pp.74-83, 2004.
DOI : 10.1016/S0016-5085(03)00939-9

B. Werle-lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen et al., Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ???, Gastroenterology, vol.126, issue.7, pp.1750-1758, 2004.
DOI : 10.1053/j.gastro.2004.03.018

L. M. Wolters, B. E. Hansen, H. G. Niesters, D. Dehertogh, and R. A. De-man, Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B, Journal of Hepatology, vol.37, issue.1, pp.137-181, 2002.
DOI : 10.1016/S0168-8278(02)00115-0

D. K. Wong, A. M. Cheung, K. O-'rourke, C. D. Naylor, A. S. Detsky et al., Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B, Annals of Internal Medicine, vol.119, issue.4, pp.312-335, 1993.
DOI : 10.7326/0003-4819-119-4-199308150-00011

H. Yang, C. Westland, S. Xiong, and W. E. Delaney, In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector, Antiviral Research, vol.61, issue.1, pp.27-36, 2004.
DOI : 10.1016/j.antiviral.2003.07.003

H. I. Yang, S. N. Lu, Y. F. Liaw, S. L. You, C. A. Sun et al., Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma, New England Journal of Medicine, vol.347, issue.3, pp.168-74, 2002.
DOI : 10.1056/NEJMoa013215

M. F. Yuen, H. J. Yuan, D. K. Wong, J. C. Yuen, W. M. Wong et al., Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications, Gut, vol.54, issue.11, pp.1610-1614, 2005.
DOI : 10.1136/gut.2005.065136

F. Zoulim, A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection, Drug Safety, vol.29, issue.2, pp.497-510, 2002.
DOI : 10.2165/00002018-200225070-00004

F. Zoulim, Treatment of pre- and post-liver transplantation HBV infection: Should we aim at combination therapy?, Hepatology, vol.46, issue.6, pp.1353-1358, 2003.
DOI : 10.1016/j.hep.2003.10.001

F. Zoulim, Antiviral Therapy of Chronic Hepatitis B: Can We Clear the Virus and Prevent Drug Resistance?, Antiviral Chemistry and Chemotherapy, vol.64, issue.6, pp.299-305, 2004.
DOI : 10.1053/jhep.2001.23045

F. Zoulim, Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection, Antiviral Research, vol.64, issue.1, pp.1-15, 2004.
DOI : 10.1016/S0166-3542(04)00162-7
URL : https://hal.archives-ouvertes.fr/inserm-00136413

F. Zoulim, New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA, Journal of Hepatology, vol.42, issue.3, pp.302-310, 2005.
DOI : 10.1016/j.jhep.2004.12.015

F. Zoulim, Entecavir: A new treatment option for chronic hepatitis B, Journal of Clinical Virology, vol.36, issue.1, 2006.
DOI : 10.1016/j.jcv.2006.01.010

F. Zoulim, T. Poynard, and F. Degos, A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine, Journal of Viral Hepatitis, vol.9, issue.4, 2006.
DOI : 10.1111/j.1572-0241.2005.41957.x
URL : https://hal.archives-ouvertes.fr/inserm-00135954